missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD45 Monoclonal Antibody (2D1), Brilliant Violet™ 711, eBioscience™, Invitrogen™
Mouse Monoclonal Antibody
Marca: Invitrogen 407-9459-41
Este artículo no se puede devolver.
Vea la política de devoluciones
Descripción
CD45 Monoclonal antibody specifically detects CD45 in Human samples. It is validated for Flow Cytometry
Especificaciones
CD45 | |
Monoclonal | |
5 μL/Test | |
PBS with BSA and 0.09% sodium azide; pH 7.2 | |
P08575 | |
Mouse | |
25 Tests | |
Primary | |
Human | |
Antibody | |
IgG1 κ |
Flow Cytometry | |
2D1 | |
Brilliant Violet 711 | |
PTPRC | |
B220; cd45; CD45 antigen; CD45 antigen isoform 1 precursor; CD45 antigen isoform 2 precursor; CD45 antigen isoform 3 precursor; CD45 antigen isoform 4 precursor; CD45 antigen isoform 5 precursor; CD45 antigen isoform 6 precursor; CD45R; GP180; Lca; L-CA; leucocyte common antigen; leukocyte common antigen; leukocyte common antigen A; leukocyte common antigen B; leukocyte common antigen, CD45; loc; LOW QUALITY PROTEIN: receptor-type tyrosine-protein phosphatase C; LY5; Ly-5; lymphocyte antigen 5; lymphocyte common antigen; Lyt-4; membrane tyrosine phosphatase; protein tyrosine phosphatase lambda; protein tyrosine phosphatase receptor type C; protein tyrosine phosphatase, receptor type C; protein tyrosine phosphatase, receptor type, C; protein tyrosine phosphatase, receptor type, c polypeptide; Protein tyrosine phosphatase, receptor-type, c polypeptide; protein tyrosine phosphatase; alternatively spliced; Ptprc; Receptor-type tyrosine-protein phosphatase C; RT7; T200; T200 glycoprotein; T200 leukocyte common antigen; T220 and B220 | |
Affinity chromatography | |
RUO | |
5788 | |
4° C, store in dark, DO NOT FREEZE! | |
Liquid |
Corrección del contenido de un producto
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.
Título del producto
CD45 Monoclonal Antibody (2D1), Brilliant Violet™ 711, eBioscience™, Invitrogen™ > 25 Tests, Brilliant Violet™ 711
¿Detecta una oportunidad de mejora?Comparta una corrección de contenido